Sinopharm unit gets approval for clinical trials of mRNA COVID vaccine

The unit, based in the commercial hub of Shanghai, has built a research and development platform, as well as workshops with annual production capacity of 2 billion doses of mRNA vaccine, Sinopharm added.

Reuters

Published:20th Jan, 2023 at 10:28 AM

LONDON: Sinopharm's biotech unit has obtained regulatory approval for clinical trials of its mRNA COVID-19 vaccine against the Omicron variant, the company said on Friday.

The unit, based in the commercial hub of Shanghai, has built a research and development platform, as well as workshops with annual production capacity of 2 billion doses of mRNA vaccine, Sinopharm added.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Sinopharm unit gets approval for clinical trials of mRNA COVID vaccine

The unit, based in the commercial hub of Shanghai, has built a research and development platform, as well as workshops with annual production capacity of 2 billion doses of mRNA vaccine, Sinopharm added.

Also Read

Railway fares to go up from Dec 26, to yield Rs 600 crore extra revenue

Bangladesh: India suspends visa services after violent attack near its Chittagong mission

CM Stalin slams AIADMK leader EPS for keeping mum over MGNREGA issue

Delhi airport: 97 flights cancelled, over 200 services delayed due to fog

Fringe forces cannot derail Stalin govt, says Minister Sekarbabu, hits back at H Raja